Symbols

SRRK

Scholar Rock Holding·NASDAQ

--(--)

SRRK fundamentals

SRRK Q4 2025 Earnings

Scholar Rock Holding (SRRK) released its earnings on Mar 3, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.88 (YoY -41.94%), beat estimates.

Revenue / YoY

EPS / YoY

-0.88

-41.94%

Report date

Mar 3, 2026

SRRK Earnings Call Summary for Q4,2025

2026 Regulatory Milestone: BLA resubmission and U.S. launch on track, contingent on successful FDA reinspection of the Catalent facility.
Pipeline Expansion: SRK-439 Phase I enrollment complete; subcu apitegromab Phase I data supports PK comparability to IV.
Financial Strength: $368M cash on hand + $550M debt facility provide >$900M liquidity post-approval.
Commercial Readiness: U.S. launch infrastructure built with 140 SMA centers and 10,000+ home infusion nurses.
European Expansion: EMA decision expected mid-2026, with Germany as the first European launch market.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Scholar Rock Holding (SRRK) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Scholar Rock Holding (SRRK)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Scholar Rock Holding (SRRK)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Scholar Rock Holding (SRRK)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown